×

Lightning Round: I say this is an opportunity

It's that time again! The Lightning Round bell has rung, and Jim Cramer gives his take on a few favorite audience stocks:

Statoil: "Not that crazy about STO. I like as a growth oil EOG and I've been bottom fishing with that Royal Dutch...Nothing happened with that deal but maybe they can get in on that Petrobras? But STO, no thank you."

TG Therapeutics: "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I think that company is good and I say this is an opportunity."

Realty Income Corporation: "Realty Company is okay, but frankly we like Federal Realty and we like Ventas. Those are the two REITs that we think best about."

Ship Finance International: "I am worried about that yield. It is a suspicious red flag yield. It seems a little bit too high, and I do think by the way that Nordic American...you can probably make some money on that one because I do believe that rates are staying high."

Sturm, Rutger & Company: "It's okay. It's not one I get behind, I'm just not a big believer in the gun stocks. I'm such a huge believer in the defense stocks, and I don't want to stray away from Northrop, Lockheed or from Orbital."

Emerge Energy Services: "I don't want to be in that sand fracking business...All the energy plays are going down including frack sand, which was the problem at Union Pacific. Let's be careful."

KKR & Co LP: "I like KKR and I like Blackstone. But I remain faithful to KKR."

Phillips 66: "I like Phillips 66. I think it's doing quite well and I don't want to sell that stock."

----------------------------------------------------------
Read more from Mad Money with Jim Cramer
Cramer Remix: I fear this financial
Cramer: Don't dare invest without these
Cramer game plan: Getting in on Buffett's top bank
----------------------------------------------------------

Advaxis: "This is a pure spec, cancer vaccine play in many ways. I'm not getting behind the vaccine plays, but I certainly bless it as a speculation."

Ziopharm Oncology: "That stock got hammered on its secondary. Let me circle back on that, I'm surprised it didn't bounce back."

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram - Vine

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com